Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000657

Drug Information
SynonymsC419708; EN002708; CHEMBL939; NCGC00159455-03; AC-1556; CHEBI:49668; UNII-S65743JHBS; KBioSS_002241; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; MolPort-000-883-335; NSC715055; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine; ZD-1839, Iressa, Gefitinib; D01977; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-; Iressa; I01-1227; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; Gefitinib; Iressa (TN); N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; Kinome_3321; nchembio866-comp14; CID123631; ZD1839; DB00317; Bio-0046; nchembio.117-comp18; BCB03_000781; Gefitinib [USAN]; Iressa(TM); DB07998; Gefitinib, Iressa, ZD1839; IRE; Kinome_3322; LS-139916; STK621310; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 184475-35-2; ZD 1839; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-; K00240; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; CCRIS 9011; Gefitini; Iressa; Irressat; FT-0081035; S1025_Selleck; NCGC00159455-02; CU-00000000396-1; ZINC19632614; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-; AKOS000280752; AC1L3X0A; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; Gefitinib (JAN/USAN/INN); EC-000.2409; ZD-1839; HMS2089B19    
Trade NameIressa    
IndicationCancersLaunched    [1]
Head & neck cancerPhase III    [1]
Urethral, bladder, ovarian, prostate, breast cancerPhase II    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 184475-35-2
PubChem Compound IDCID 123631.    
PubChem Substance IDSID 532631.    
SuperDrug ATC IDL01XX31;    
SuperDrug CAS ID184475352;    
TargetEpidermal growth factor receptorInhibitor[2][3]
Epidermal growth factor receptorInhibitor[4][5]
Ref 1Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. To Reference
Ref 2Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72. To Reference
Ref 3'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 2004 Feb;14(1):33-40. To Reference
Ref 4A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 5AstraZeneca. Product Development Pipeline. January 29 2009. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543